Abstract
Purpose of Review
Chronic knee pain remains a debilitating condition that remains difficult to manage. The purpose of this review, therefore, is to summarize current understanding of alpha-2-microglobulin in the treatment of osteoarthritic knee pain. Furthermore, we investigate its role in the anti-inflammatory properties of platelet-rich plasma (PRP).
Recent Findings
Alpha-2-microglobulin, a 720-kD protein complex, is an active protease inhibitor with tremendous anti-inflammatory properties in animal models. A growing body of evidence suggests that this complex is the most instrumental factor for cartilage preservation in PRP injections.
Summary
As an active component of platelet-rich plasma’s anti-inflammatory properties, alpha-2-microglobulin has been shown to be an active inhibitor of joint degeneration, cartilage preservation, and improvement in quality of life for patients with knee osteoarthritis compared with a multitude of other modalities.
Similar content being viewed by others
Change history
08 February 2020
The original publication listed author Alan Kaye as “A. Kaye,” but his name should read “A.D. Kaye.” The correct author name is presented in this article.
08 February 2020
The original publication listed author Alan Kaye as ���A. Kaye,��� but his name should read ���A.D. Kaye.��� The correct author name is presented in this article.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Holtedahl R. Atraumatic knee pain. Tidsskr Nor Legeforen. 2018;138(5). https://doi.org/10.4045/tidsskr.17.0594.
Arthritis Basics. CDC. Retrieved from https://www.cdc.gov/arthritis/basics/index.html. 1 Jan 2019.
Cisternas MG, Murphy L, Sacks JJ, Solomon DH, Pasta DJ, Helmick CG. Alternative methods for defining osteoarthritis and the impact on estimating prevalence in a US population-based survey. Arthritis Care Res. 2016;68(5):574–80.
Ourradi K, Sharif M. Biomarkers for diagnosis of osteoartritis. JSM Bone Joint Dis. 2017;1(1):1002.
Hussain SM, Neilly DW, Baliga S, Patil S, Meek R. Knee osteoarthritis: a review of management options. Scott Med J. 2016;61(1):7–16. https://doi.org/10.1177/0036933015619588.
Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fam Physician. 2012;85(1):49–56.
Braun HJ, Gold GE. Diagnosis of osteoarthritis: imaging. Bone. 2011;51(2):278–88.
Abhishek A, Doherty M. Diagnosis and clinical presentation of osteoarthritis. Rheum Dis Clin N Am. 2013;39(1):45–66. https://doi.org/10.1016/j.rdc.2012.10.007.
Swagerty DL, Hellinger D. Radiographic assessment of osteoarthritis. Am Fam Physician. 2001;64(2):279–87.
Culvenor AG, Øiestad BE, Hart HF, Stefanik JJ, Guermazi A, Crossley KM. Prevalence of knee osteoarthritis features on magnetic resonance imaging in asymptomatic uninjured adults: a systematic review and meta-analysis. Br J Sports Med. Published Online First: 09 June 2018. https://doi.org/10.1136/bjsports-2018-099257.
Yucesoy B, Charles LE, Baker B, Burchfiel CM. Occupational and genetic risk factors for osteoarthritis: a review. Work. 2015;50(2):261–73.
Glyn-Jones S, Palmser AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthritis. Lancet. 2015;386(9991):376–87. https://doi.org/10.1016/S0140-6736(14)60802-3.
Murray CJ, Lopez AD. Evidence-based health policy—lessons from the global burden of disease study. Science. 1996;274(5288):740–3.
Kulkarni K, Karssiens T, Kumar V, Pandit H. Obesity and osteoarthritis. Maturitas. 2016;89:22–8. https://doi.org/10.1016/j.maturitas.2016.04.006.
Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum. 2009;60(12):3546–53.
Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072.
Wan R, Hu J, Zhou Q, Wang J, Liu P, Wei Y. Application of co-expressed genes to articular cartilage: new hope for the treatment of osteoarthritis (review). Mol Med Rep. 2012;6(1):16–8. https://doi.org/10.3892/mmr.2012.859.
Luan Y, Kong L, Howell DR, Ilalov K, Fajardo M, Bai XH, et al. Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-microglobulin. Osteoarthr Cartil. 2008;16(11):1413–20.
Cuellar JM, Cuellar VG, Scuderi GJ. α2-microglobulin autologous protease inhibition technology. Phys Med Rehabil Clin N Am. 2016;27:909–18.
Scuderi GJ, Golish SR, Cook FF, Cuellar JM, Bowser RP, Hanna LS. Identification of a novel fibronectin-aggrecan complex in the synovial fluid of knees with painful meniscal injury. J Bone Joint Surg Am. 2011 Feb 16;93(4):336–40. https://doi.org/10.2106/JBJS.J.00718.
Larsson S, Lohmander LS, Struglics A. Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study. Arthritis Res Ther. 2009;11(3):R92.
Maniar KH, Jones IA, Gopalakrishna R, Vangsness CT Jr. Lowering side effects of NSAID usage in osteoarthritis: recent attempts at minimizing dosage. Expert Opin Pharmacother. 2018;19(2):93–102. https://doi.org/10.1080/14656566.2017.1414802.
Law TY, Nguyen C, Frank RM, Rosas S, McCormick F. Current concepts on the use of corticosteroid injections for knee osteoarthritis. Phys Sportsmed. 2015;43(3):269–73. https://doi.org/10.1080/00913847.2015.1017440.
Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA. 2018;320(24):2564–79. https://doi.org/10.1001/jama.2018.19319.
Bliddal H, Leeds AR, Christensen R. Osteoarthritis, obesity and weight loss: evidence, hypotheses and horizons - a scoping review. Obes Rev. 2014;15(7):578–86.
Rizzo J. Patients’ mental models and adherence to outpatient physical therapy home exercise programs. Physiother Theory Pract. 2015;31(4):253–9. https://doi.org/10.3109/09593985.2014.1003117.
Hackinger S, Trajanoska K, Styrkarsdottir U, Zengini E, Steinberg J, Ritchie G, et al. Evaluation of shared genetic aetiology between osteoarthritis and bone mineral density identifies SMAD3 as a novel osteoarthritis risk locus. Hum Mol Genet. 2017;26(19):3850–8.
Evidence Development and Standards Branch. Health Quality Ontario. Arthroscopic debridement of the knee: an evidence update. Ont Health Technol Assess Ser. 2014;14(13):1–43 Published 2014 Nov 1.
van der Woude J, Wiegant K, van Heerwaarden RJ, Spruijt S, van Roermund PM, Custers R, et al. Knee joint distraction compared with high tibial osteotomy: a randomized controlled trial. Knee Surg Sports Traumatol Arthrosc. 2016;25(3):876–86.
Intema F, Van Roermund PM, Marijnissen AC, Cotofana S, Eckstein F, Castelein RM, et al. Tissue structure modification in knee osteoarthritis by use of joint distraction: an open 1-year pilot study. Ann Rheum Dis. 2011;70(8):1441–6.
Wang S, Wei X, Zhou J, Zhang J, Li K, Chen Q, et al. Identification of alpha 2 microglobulin (A2M) as a master inhibitor of cartilage degrading factors that attenuates post-traumatic osteoarthritis progression. Arthritis Rheum. 2014;66(7):1843–53. https://doi.org/10.1002/art.38576.
Doan N, Gettins PG. Human alpha2-macroglobulin is composed of multiple domains, as predicted by homology with complement component C3. Biochem J. 2007;407(1):23–30.
Sottrup-Jensen L, Stepanik TM, Kristensen T, Wjerzbicki DM, Jones CM, Lenblad PB, et al. Primary structure of human alpha 2-macroglobulin. V. The complete structure. J Biol Chem. 1984;259(13):8318–27.
Zhang Y, Wei X, Browning S, Scuderi G, Hanna LS, Wei L. Targeted designed variants of alpha-2-macroglobulin (A2M) attenuate cartilage degeneration in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Arthritis Res Ther. 2017;19(175). https://doi.org/10.1186/s13075-017-1363-4.
Wang S, Wei X, Zhou J, Zhang J, Li K, Chen Q, Terek R, Fleming BC, Goldring MB, Ehrlich MG, Zhang G, … Wei L Identification of Α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis. Arthritis Rheumatol. 2014;66(1843)1853. https://doi.org/10.1002/art.38576.
Cuellar JM, Browning SR, Cuellar VG, Golish SR, Hanna L, Scuderi G. Poster 10 is there a chondroprotective effect of autologous platelet integrated concentrate (APIC) on an osteoarthritis (OA) rabbit model? A pilot study. Pm&R. 2012. https://doi.org/10.1016/j.pmrj.2012.09.640.
Tortorella MD, Arner EC, Hills R, Easton A, Korte-Sarfaty J, Fok K, et al. Α2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J Biol Chem. 2004;279:17554–61. https://doi.org/10.1074/jbc.M313041200.
Cole BJ, Karas V, Hussey K, Pilz K, Fortier LA. Hyaluronic acid versus platelet-rich plasma: a prospective, double-blind randomized controlled trial comparing clinical outcomes and effects on intra-articular biology for the treatment of knee osteoarthritis. Am J Sports Med. 2017;45:339–46. https://doi.org/10.1177/0363546516665809.
Paterson KL, Nicholls M, Bennell KL, Bates D. Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: a double-blind, randomized controlled pilot study. BMC Musculoskelet Disord. 2016;17:67. https://doi.org/10.1186/s12891-016-0920-3.
Duif C, Vogel T, Topcuoglu F, Spyrou G, von Schulze Pellengahr C, Lahner M. Does intraoperative application of leukocyte-poor platelet-rich plasma during arthroscopy for knee degeneration affect postoperative pain, function and quality of life? A 12-month randomized controlled double-blind trial. Arch Orthop Trauma Surg. 2015;135:971–7. https://doi.org/10.1007/s00402-015-2227-5.
Spaková T, Rosocha J, Lacko M, Harvanová D, Gharaibeh A. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil. 2012;91:411–7. https://doi.org/10.1097/PHM.0b013e3182aab72.
Kon E, Buda R, Filardo G, Di Martino A, Timoncini A, Cenacchi A, et al. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy. 2011;27:1490–501. https://doi.org/10.1016/j.arthro.2011.05.011.
Charousset C, Zaoui A, Bellaiche L, Bouyer B. Are multiple platelet-rich plasma injections useful for treatment of chronic patellar tendinopathy in athletes?: a prospective study. Am J Sports Med. 2014;42:906–11. https://doi.org/10.1177/0363546513519964.
Li M, Zhang C, Ai Z, Yuan T, Feng Y, Jia W. Therapeutic effectiveness of intra-knee-articular injection of platelet-rich plasma on knee articular cartilage degeneration. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011.
Chen SH, Kuan TS, Kao MJ, Wu WT, Chou LW. Clinical effectiveness in severe knee osteoarthritis after intra-articular platelet-rich plasma therapy in association with hyaluronic acid injection: three case reports. Clin Interv Aging. 2016;Volume 11:1213–9. https://doi.org/10.2147/CIA.S114795.
Gobbi A, Karnatzikos G, Mahajan V, Malchira S. Platelet-rich plasma treatment in symptomatic patients with knee osteoarthritis: preliminary results in a group of active patients. Sports Health. 2012;4:162–72. https://doi.org/10.1177/1941738111431801.
Gibbs N, Diamond R, Sekyere EO, Thomas WD. Management of knee osteoarthritis by combined stromal vascular fraction cell therapy, platelet-rich plasma, and musculoskeletal exercises: a case series. J Pain Res. 2015. https://doi.org/10.2147/JPR.S92090.
Bowman KF, Muller B, Middleton K, Fink C, Harner CD, Fu FH. Progression of patellar tendinitis following treatment with platelet-rich plasma: case reports. Knee Surg Sports Traumatol Arthrosc. 2013;21:2035–9. https://doi.org/10.1007/s00167-013-2549-1.
ClinicalTrials.gov. New York (NY): New York University School of Medicine 2017 Nov 1–2019 Mar 12. Identifier NCT03656575, Reduction of pro-inflammatory synovial fluid biomarkers in osteoarthritis of the knee with alpha-2 macroglobulin; https://clinicaltrials.gov/ct2/show/NCT03656575?cond=Reduction+of+Pro-Inflammatory+Synovial+Fluid+Biomarkers+in+Osteoarthritis+of+the+Knee+With+Alpha-2+Macroglobulin&rank=1.
Scuderi GJ. ClinicalTrials.gov. Palo Alto (CA): Stanford University Hospital 2017 Oct 9. Identifier NCT01613833, Serum and synovium protease inhibitor levels in primary and secondary osteoarthritic joints; https://clinicaltrials.gov/ct2/show/NCT01613833
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Hot Topics in Pain and Headache
Rights and permissions
About this article
Cite this article
Orhurhu, V., Schwartz, R., Potts, J. et al. Role of Alpha-2-Microglobulin in the Treatment of Osteoarthritic Knee Pain: a Brief Review of the Literature. Curr Pain Headache Rep 23, 82 (2019). https://doi.org/10.1007/s11916-019-0822-9
Published:
DOI: https://doi.org/10.1007/s11916-019-0822-9